Merck and Daiichi Sankyo Strike Cancer Drug Alliance, PharmaEssentia Enters License Agreement for Myeloid Immune Checkpoint Antibody Candidate

Merck and Daiichi Sankyo strike a cancer drug alliance, highlighting the pharmaceutical industry's interest in antibody-drug conjugates (ADCs). EpimAb Biotherapeutics and Almirall announce a license agreement to develop bispecific antibodies. I-Mab and ABL Bio provide updates on their PD-L1 and 4-1BB bispecific antibody candidate. PharmaEssentia enters into a license agreement for a myeloid immune checkpoint antibody candidate. The global biosimilar monoclonal antibodies market is projected to reach USD 65.42 billion by 2032.